Published • loading... • Updated
Postmarketing VigiBase analysis links GLP-1 therapies to neuropsychiatric
Summary by BIOENGINEER.ORG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Postmarketing VigiBase analysis links GLP-1 therapies to neuropsychiatric
A new post-marketing analysis has mined the World Health Organization’s VigiBase database to quantify neuropsychiatric adverse event reports linked to GLP-1–based therapies. Researchers focused on signals related to symptoms such as mood disturbances, anxiety, confusion, and other psychiatric presentations that can emerge after treatment. Because these drugs are widely used for […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
